Newer drugs are more targeted than standard agents, but their incorporation into treatment regimens is challenging because of the risk of cardiovascular and infectious adverse events.
Addressing this autoimmune disorder characterized by thrombosis or pregnancy morbidity coupled with persistent antiphospholipid antibodies involves identifying and mitigating thrombosis risk factors.